- Single-Asset Focused Collaboration, License, and Option Agreement Combines Tubulis’ Differentiated ADC Platform Technologies with Gilead’s Oncology Research and Development Expertise 
- Agreement Provides Gilead with Exclusive Option to License the Resulting ADC Program for Further Development 

FOSTER CITY, Calif & MUNICH--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis today announced that they have entered into an exclusive option and license agreement to discover and develop an antibody-drug conjugate (ADC) against a solid tumor target.

Through this agreement, Gilead will gain access to Tubulis’ proprietary Tubutecan and Alco5 platforms. The companies will collaborate to select the best technology to utilize, with Tubulis leading discovery and development efforts to design a Topoisomerase I inhibitor-based ADC candidate with superior biophysical properties and stability to address current treatment challenges such as durability and off-target toxicity.

https://www.businesswire.com/news/home/20241203665344/en/Gilead-and-Tubulis-Enter-Into-Exclusive-Option-and-License-Agreement-to-Develop-ADC-Candidate-for-Select-Solid-Tumor-Target